Available data indicate that argireline exhibits a robust safety profile when applied topically.
Indeed, clinical studies on argireline report no significant adverse effects : neither notable allergic reactions, skin irritation, nor documented toxicity at the doses used. However, published toxicological data remain limited: an in vitro study demonstrated a dose-dependent antiproliferative effect on several human cell lines, including fibroblasts, but only at concentrations 18 to 10,000 times higher than those necessary to induce the cytotoxicity of doxorubicin, a reference compound. These levels bear no relation to the concentrations used in cosmetics, which greatly reduces their clinical relevance.
More rarely, adverse effects related to argireline have been reported in specific contexts, notably via injection. One case describes the appearance of a Mycobacterium abscessus on the forehead and temples of a patient following argireline injections, presenting with erythema, nodules, and an abscess requiring five months of antibiotic therapy. That said, this type of complication is not linked to the peptide itself but rather to the invasive nature of the procedure and the associated risk of contamination. This case underscores that the risks only increase when straying from standard topical use : under normal conditions of use — topical application, controlled concentrations, and formulation — Argireline is regarded as a safe active ingredient.
Note : To date, no data indicate that argireline poses any risk to pregnant women. However, in the absence of specific studies and as a precautionary principle, it is generally advised to consult your physician.